taken from my brokers rag1 Dec 2017 11:48
Broker UBS believes things will likely get tougher for
GlaxoSmithKline before they begin to improve. However, the broker has maintained
Its target price and upgraded their �buy� recommendation, stating that concerns over the continuing earnings decline are overdone. The broker noted that a series of downward earnings revisions have reinvigorated the debate on whether the company�s dividend was secure.
The company has now proposed a dividend of 19p for the quarter, and continues to expect a total pay-out of 80p for the year, targeting to maintain this level in 2018. Glaxo�s HIV joint venture ViiV has been the main engine of growth for the company, accounting for a third of the group�s earnings. However, with competitor Gilead Sciences re-entering the market in 2018, Glaxo is expected to lose market share. The broker notes that the recent share price decline leaves it trading on 13 time�s forward price to earnings ratio. They believe this shows the uncertainties priced in and, after 2 years of 80p dividends, investors will then be able to decide if �there is gold at the end of the rainbow�.